Erratum to: The Omega-3 Fatty Acid Eicosapentaenoic Acid Accelerates Disease Progression in a Model of Amyotrophic Lateral Sclerosis(PLOS ONE (2013) 8:4 (e61626) DOI: 10.1371/journal.pone.0061626);The Omega-3 Fatty Acid Eicosapentaenoic Acid Accelerates Disease Progression in a Model of Amyotrophic Lateral Sclerosis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yip, Ping K ^a   Pizzasegola, Chiara ^b   Gladman, Stacy ^a   Biggio, Maria Luigia ^b   Marino, Marianna ^b   Jayasinghe, Maduka ^a   Ullah, Farhan ^a   Dyall, Simon C ^a,c   Malaspina, Andrea ^a,d   Bendotti, Caterina ^b   Michael Titus, Adina ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF ROEHAMPTON   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCINE; ICOSAPENTAENOIC ACID; 3 NITROTYROSINE; 3-NITROTYROSINE; DRUG DERIVATIVE; MUTANT PROTEIN; SUPEROXIDE DISMUTASE; TYROSINE;

AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL LOSS; CELL VACUOLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DISEASE MODEL; FATTY ACID OMEGA OXIDATION; FEMALE; HISTOPATHOLOGY; MALE; MICROGLIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; GENETICS; GLIA; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; METABOLISM; MOTONEURON; MOTOR ACTIVITY; NERVE FIBER; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; SURVIVAL; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AXONS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; LIPID METABOLISM; LIPID PEROXIDATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR NEURONS; MUTANT PROTEINS; NEUROGLIA; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS; TYROSINE; VACUOLES;

EID: 84876451013     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0307246     Document Type: Erratum

References (58)

1. Cleveland DW, Rothstein JD, (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819.
2. McDermott CJ, Shaw PJ, (2008) Diagnosis and management of motor neurone disease. BMJ 336: 658-662.
3. Miller RG, Mitchell JD, Lyon M, Moore DH, (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev pp. CD001447.
4. Simopoulos AP, (1999) Essential fatty acids in health and chronic disease. Am J Clin Nutr 70: 560S-569S.
5. Huang WL, King VR, Curran OE, Dyall SC, Ward RE, et al. (2007) A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 130: 3004-3019.
6. King VR, Huang WL, Dyall SC, Curran OE, Priestley JV, et al. (2006) Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci 26: 4672-4680.
7. Lim SN, Huang W, Hall JC, Ward RE, Priestley JV, et al. (2010) The acute administration of eicosapentaenoic acid is neuroprotective after spinal cord compression injury in rats. Prostaglandins Leukot Essent Fatty Acids 83: 193-201.
8. Dyall SC, Michael GJ, Michael-Titus AT, (2010) Omega-3 fatty acids reverse age-related decreases in nuclear receptors and increase neurogenesis in old rats. J Neurosci Res 88: 2091-2102.
9. Dyall SC, Michael-Titus AT, (2008) Neurological benefits of omega-3 fatty acids. Neuromolecular Med 10: 219-235.
10. Kim HY, Akbar M, Kim YS, (2010) Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 82: 165-172.
11. Salem N Jr, Litman B, Kim HY, Gawrisch K, (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36: 945-959.
12. Bruijn LI, Miller TM, Cleveland DW, (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723-749.
13. Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, et al. (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258: 613-617.
14. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, et al. (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70: 1004-1009.
15. Gonzalez de Aguilar JL, Dupuis L, Oudart H, Loeffler JP, (2005) The metabolic hypothesis in amyotrophic lateral sclerosis: insights from mutant Cu/Zn-superoxide dismutase mice. Biomed Pharmacother 59: 190-196.
16. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.
17. Peviani M, Caron I, Pizzasegola C, Gensano F, Tortarolo M, et al. (2010) Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. CNS Neurol Disord Drug Targets 9: 491-503.
18. Bendotti C, Carri MT, (2004) Lessons from models of SOD1-linked familial ALS. Trends Mol Med 10: 393-400.
19. Grignaschi G, Zennaro E, Tortarolo M, Calvaresi N, Bendotti C, (2007) Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotroph Lateral Scler 8: 31-35.
20. Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, et al. (2009) Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 10: 221-228.
21. Dyall SC, Michael GJ, Whelpton R, Scott AG, Michael-Titus AT, (2007) Dietary enrichment with omega-3 polyunsaturated fatty acids reverses age-related decreases in the GluR2 and NR2B glutamate receptor subunits in rat forebrain. Neurobiol Aging 28: 424-439.
22. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
23. Manku MS, Horrobin DF, Huang YS, Morse N, (1983) Fatty acids in plasma and red cell membranes in normal humans. Lipids 18: 906-908.
24. Soleman S, Yip P, Leasure JL, Moon L, (2010) Sustained sensorimotor impairments after endothelin-1 induced focal cerebral ischemia (stroke) in aged rats. Exp Neurol 222: 13-24.
25. Nardo G, Pozzi S, Mantovani S, Garbelli S, Marinou K, et al. (2009) Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal 11: 1559-1567.
26. Jokic N, Yip PK, Michael-Titus A, Priestley JV, Malaspina A, (2010) The human G93A-SOD1 mutation in a pre-symptomatic rat model of amyotrophic lateral sclerosis increases the vulnerability to a mild spinal cord compression. BMC Genomics 11: 633.
27. Yip PK, Kaan TK, Fenesan D, Malcangio M, (2009) Rapid isolation and culture of primary microglia from adult mouse spinal cord. J Neurosci Methods 183: 223-237.
28. Yamada S, Funada T, Shibata N, Kobayashi M, Kawai Y, et al. (2004) Protein-bound 4-hydroxy-2-hexenal as a marker of oxidized n-3 polyunsaturated fatty acids. J Lipid Res 45: 626-634.
29. Clement MV, Hirpara JL, Pervaiz S, (2003) Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ 10: 1273-1285.
30. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL, (2000) Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 20: 660-665.
31. Lino MM, Schneider C, Caroni P, (2002) Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 22: 4825-4832.
32. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA, (2001) Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 21: 3369-3374.
33. Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, et al. (2001) Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 21: 9246-9254.
34. Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L, (2006) Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. J Neurochem 97: 687-696.
35. Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, et al. (2007) Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 130: 3111-3123.
36. Shibata N, Yamada S, Uchida K, Hirano A, Sakoda S, et al. (2004) Accumulation of protein-bound 4-hydroxy-2-hexenal in spinal cords from patients with sporadic amyotrophic lateral sclerosis. Brain Res 1019: 170-177.
37. Chen CT, Liu Z, Ouellet M, Calon F, Bazinet RP, (2009) Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids 80: 157-163.
38. Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, et al. (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 196: 266-272.
39. Song C, Horrobin D, (2004) Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration. J Lipid Res 45: 1112-1121.
40. Song C, Leonard BE, Horrobin DF, (2004) Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats. Stress 7: 43-54.
41. Trebble TM, Stroud MA, Wootton SA, Calder PC, Fine DR, et al. (2005) High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. Br J Nutr 94: 253-261.
42. Ziboh VA, Cohen KA, Ellis CN, Miller C, Hamilton TA, et al. (1986) Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Modulation of clinical course of psoriatic subjects. Arch Dermatol 122: 1277-1282.
43. Simopoulos AP, (2007) Omega-3 fatty acids and athletics. Curr Sports Med Rep 6: 230-236.
44. Huntington Study Group TREND-HD Investigators (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65: 1582-1589.
45. Boston PF, Bennett A, Horrobin DF, Bennett CN, (2004) Ethyl-EPA in Alzheimer's disease-a pilot study. Prostaglandins Leukot Essent Fatty Acids 71: 341-346.
46. Martins JG, (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28: 525-542.
47. Kong J, Xu Z, (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18: 3241-3250.
48. Kim YJ, Nakatomi R, Akagi T, Hashikawa T, Takahashi R, (2005) Unsaturated fatty acids induce cytotoxic aggregate formation of amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutants. J Biol Chem 280: 21515-21521.
49. Liu J, Lillo C, Jonsson PA, Vande Velde C, Ward CM, et al. (2004) Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43: 5-17.
50. Banci L, Bertini I, Boca M, Girotto S, Martinelli M, et al. (2008) SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. PLoS One 3: e1677.
51. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, et al. (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43: 19-30.
52. Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, et al. (2010) Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 67: 575-587.
53. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH, (2008) CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 105: 15558-15563.
54. Henkel JS, Beers DR, Zhao W, Appel SH, (2009) Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 4: 389-398.
55. Liao B, Zhao W, Beers DR, Henkel JS, Appel SH, (2012) Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 237: 147-152.
56. Vargas MR, Johnson DA, Johnson JA, (2011) Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model. Neurobiol Dis 43: 543-551.
57. Audet JN, Soucy G, Julien JP, (2012) Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. Neuroscience 209: 136-143.
58. Patel BP, Safdar A, Raha S, Tarnopolsky MA, Hamadeh MJ, (2010) Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS One 5: e9386.